NYSE · PHARMACEUTICAL PREPARATIONS · MID CAP
Emergent Biosolutions Inc. EBS
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$742.9M
▼ 28.8% vs FY2024
EPS · FY25
$0.93
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
10.5%
Net margin · FY25
7.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 742.9M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
7 cents of every revenue dollar became profit this year.
Per share
USD 0.93
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
10.5%
Return on equity, FY2025
ROE
Operating margin13.5%
Net margin7.1%
Return on assets3.9%
Each USD of equity produced 10 cents of profit this year.
Returned to shareholders
USD 24.9M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 24.9M
Share of profit47.3%
Consecutive raises—
USD 24.9M in buybacks — 47% of the year's profit went back to shareholders.
Growth
−14.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−12.7%
−14.0%
+4.3%
+6.6%
Net income
−29.7%
−1.8%
+0.1%
EPS, diluted
−30.4%
−4.1%
−3.5%
Returned to shareholders
−32.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years−1.9%
Change, 10 years+32.2%
The share count shrank 2% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.3B
total assets, end of FY2025
Total assetsUSD 1.3B
EquityUSD 522.6M
CashUSD 205.4M
Gross debtUSD 572.1M
Net debtUSD 366.7M
Current ratio5.01×
Net debt stands at 70% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.7
1.0
1.0
1.1
1.8
1.6
1.1
0.8
0.6
0.5
0.5
0.4
0.3
0.3
0.3
0.3
0.2
Operating income $B
0.1
−0.1
−0.7
−0.2
0.3
0.4
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.1
0.0
EBITDA $B
0.2
0.0
−0.6
−0.0
0.5
0.5
0.2
0.1
0.2
0.1
0.2
0.1
0.1
0.0
0.0
0.1
0.0
Income tax $B
0.0
0.0
0.0
−0.0
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.1
−0.2
−0.8
−0.2
0.2
0.3
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.1
0.0
EPS, diluted $
0.93
−3.60
−14.85
−4.22
4.06
5.68
1.04
1.22
1.71
1.13
1.41
0.88
0.85
0.65
0.64
1.59
0.99
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
10.5
−33.7
−74.7
−14.1
14.3
24.1
5.2
6.5
11.0
8.7
11.4
7.0
6.7
5.5
5.9
14.0
·
Shares out B
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.04
0.04
0.04
0.04
0.04
0.04
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 53
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 4 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed